Category: Medicine and Healthcare
![Direct Biologics, LLC Announces One Year Follow Up of Pilot Safety Study of ExoFlo for Treatment of Osteoarthritis in Combat-Related Injuries](https://cdn.nwe.io/files/x/1d/b9/7423b3017e335ea9462b91c259cc.jpg)
Thirty-three Navy SEAL veterans were treated with a bone marrow mesenchymal stem cell (MSC) derived extracellular vesicle isolate product (EVIP) for Osteoarthritis (OA) of the knee, shoulder, elbow, hip, ankle, or wrist.
![Direct Biologics Announces FDA Approval for Proceeding With Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome](https://cdn.nwe.io/files/x/1d/b9/7423b3017e335ea9462b91c259cc.jpg)
Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19, Post-Acute COVID-19 Syndrome, and Chronic Post-COVID-19 Syndrome; 60-patient trial to be conducted nationally at ambulatory infusion sites
![ExoFlo™ From Direct Biologics Fulfills Urgent Medical Need in COVID-19 Treatment](https://cdn.nwe.io/files/x/1d/b9/7423b3017e335ea9462b91c259cc.jpg)
Medical professionals report dramatic and consistent success in treating patients gravely ill with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS)
![Direct Biologics Announces FDA Acceptance of IND Application for a Phase I/II Clinical Trial Studying ExoFlo for Acute Respiratory Distress Syndrome](https://cdn.nwe.io/files/x/37/b6/d1375bf5d75abc51c3cb415eb51f.jpg)
Fourth IND Application approval for investigational extracellular vesicle (EV) product ExoFlo
![Direct Biologics Granted FDA Approval of Third IND Application for the Use of ExoFlo in Mild-to-Moderate COVID-19 Infusion Therapy](https://cdn.nwe.io/files/x/37/b6/d1375bf5d75abc51c3cb415eb51f.jpg)
Extracellular vesicle product ExoFlo clinical trials to address early-stage COVID-19.
![Direct Biologics Receives FDA Approval to Proceed with Second ExoFlo IND for Post-Acute COVID-19 Syndrome and Chronic Post-COVID-19 Syndrome](https://cdn.nwe.io/files/x/1d/b9/7423b3017e335ea9462b91c259cc.jpg)
Extracellular Vesicle Isolate Product ExoFlo Shows Strong Potential to Treat COVID-19, Post-Acute COVID-19 Syndrome, and Chronic Post-COVID-19 Syndrome; 60-patient trial to be conducted nationally at ambulatory infusion sites
![Innovative Product ExoFlo™ From Direct Biologics Fulfills Unmet but Urgent Medical Need in COVID-19 Treatment](https://cdn.nwe.io/files/x/1d/b9/7423b3017e335ea9462b91c259cc.jpg)
Medical professionals report dramatic and consistent success in treating patients gravely ill with COVID-19-associated Acute Respiratory Distress Syndrome (ARDS)
![Direct Biologics Announces New Advanced Tool in Regenerative Medicine with Launch of AmnioWrap™ Placental Allograft](https://cdn.nwe.io/files/x/1d/b9/7423b3017e335ea9462b91c259cc.jpg)
New Allograft Joins Market Leading ExoFlo™ Extracellular Vesicles in Direct Biologics Product Line
![Direct Biologics Announces First Patient Treated Under Phase II Expanded Access Protocol Using ExoFlo™ to Treat COVID-19](https://cdn.nwe.io/files/x/1d/b9/7423b3017e335ea9462b91c259cc.jpg)
The expanded Access Program provides a pathway for patients to gain access to treatment with ExoFlo outside of the active Phase II research clinical trial.
![Direct Biologics Granted Expanded Access by FDA for ExoFlo™ in the Treatment of COVID-19](https://cdn.nwe.io/files/x/fd/cd/a786a92f7d8decf8ba4cbf5edf57.jpg)